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Abstract
The development of nonsurgical contraceptives for cats may facilitate population control of the
species. The purpose of this study was to investigate the utility of GnRH for immunocontraception
of male cats. Male cats (n ¼ 12) were divided into groups of three and were immunized once with
0 (sham), 50, 200, or 400 mg synthetic GnRH coupled to keyhole limpet hemocyanin and
combined with a mycobacterial adjuvant to enhance immunogenicity. GnRH antibody titer,
serum testosterone concentration, and scrotal size were determined monthly. At 6 months, semen
was collected by electroejaculation and testes were examined histologically. GnRH antibodies
were detected in all cats receiving GnRH vaccine by 1 month post-treatment and persisted
throughout the study. No dose effect of GnRH was observed; titers were not different among cats
treated with 50, 200, or 400 mg GnRH (P ¼ 0:5). Six of nine treated cats were classified as
responders based on high GnRH antibody titers (>32,000). By 3 months post-treatment, responder
cats had undetectable testosterone concentrations and testicular atrophy. Nonresponder cats had
GnRH titers of 4000–32,000 and testosterone concentrations intermediate between responder and
sham-treated cats. At 6 months, total sperm counts were similar for sham-treated cats
(3:1  1:8 106 sperm) and nonresponder cats (3:4 1:6  106 sperm; P ¼ 0:7). Only one of
the six responder cats produced sperm, none of which were motile. Combined testicular weights of
responder cats (1:3 0:1 g) were lower than sham-treated controls (5:3  1:3 g; P ¼ 0:02) and
nonresponder cats (2:9 0:3 g; P ¼ 0:02). Histologic evaluation of the testes revealed that in
responder cats, the interstitial cells that were present were pale and shrunken compared to the
plump, polyhedral eosinophilic cells in sham-treated cats. GnRH responder cats had marked
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tubular atrophy with vacuolated Sertoli cells and a paucity of germ cells. Single-dose GnRH
treatment resulted in testosterone concentrations and semen quality consistent with immunocas-
tration in a majority of cats treated.
# 2004 Elsevier Inc. All rights reserved.
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1. Introduction
The presence of large populations of feral cats leads to adverse impacts on cat welfare,
public health, and the environment. Considerable controversy exists regarding optimal
methods for controlling feral cats, including what is most practical, effective, and humane
[1]. Recently, interest has turned to immunocontraception for nonlethal control of ‘‘pest’’
species [2–4]. An ideal feline immunocontraceptive would have a high margin of safety for
treated animals and the environment, be effective in a high percentage of treated animals,
have a rapid onset and long duration of activity following a single treatment, inhibit sex
hormone production, be efficacious in all animals regardless of sex or age, and be simple to
deliver in the field.
Immunization against GnRH may achieve many characteristics of an ideal immuno-
contraceptive [5]. GnRH is a decapeptide produced in the cat by telencephalic and
diencephalic neurons and released from the median eminence into the capillary plexus
of the hypothalamus [6]. Preovulatory release of GnRH follows somatosensory stimuli
received during coitus in species such as cats in which females are induced rather than
spontaneous ovulators [7]. Therefore, antibodies against hypothalamic GnRH prevent the
normal cascade of hormone secretion that is required for gonadal regulation and gamete
production [8]. GnRH is an ideal candidate for immunocontraception of stray animals,
because a single product would be effective in both males and females [5–7]. Because the
mechanism of action is the prevention of GnRH interaction with receptors on pituitary
gonadotrope cells, all downstream hormonal activities would be inhibited. This has a
distinct advantage over immunocontraceptive strategies that preserve hormone activity,
because sex hormones contribute to undesirable nuisance behaviors such as fighting,
marking, wandering, and calling, and to adverse health effects, including mammary
neoplasia, pyometra, and prostatitis.
Effective long-term immunity classically requires a prime-boost series of immuniza-
tions, followed by additional boosting to maintain immunity throughout life. In most
wildlife situations, repeated capture for booster vaccines is not feasible. Because stray
cats, like other wild ‘‘pest’’ species, are likely to be caught only once, practicality
dictates that an effective vaccine would be capable of delivering long-lasting immunity
with a single treatment. GnRH, a decapeptide self-antigen, is a weak immunogen. To
enhance antigenicity, multimers of a synthetic GnRH have been coupled to a large
foreign protein, keyhole limpet hemocyanin (KLH), and combined with a mycobacter-
ial adjuvant. This vaccine construct blocked hormone production and pregnancy in
deer [9,10] and wild rats [11] and has been reported to induce high GnRH antibodies
in squirrels, pigs, rabbits, coyotes, horses, and bison following a single dose [12].
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The purpose of this study was to investigate the utility of GnRH for immunocontracep-
tion of cats.
2. Materials and methods
2.1. Cats
Twelve 9- to 12-month-old specific-pathogen-free male domestic shorthair cats were
acquired from a commercial vendor (Liberty Research, Liberty Corners, NJ, USA). The
cats were housed in groups of three in the Animal Care Services facilities at the University
of Florida College of Veterinary Medicine, which are accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care. Cat housing consisted of indoor
runs with raised resting benches and was climate controlled to maintain ambient tem-
peratures between 21 and 23 8C with a 14-h light:10-h dark cycle. Food and water were
available at all times. The experimental design was approved by the Institutional Animal
Care and Use Committee. All cats were surgically castrated and adopted to private homes
at the conclusion of the study.
2.2. Vaccine construction
The GnRH-KLH vaccine construct was developed by the National Wildlife Research
Center (NWRC) in Fort Collins, CO, USA. The 10-amino acid GnRH peptide hormone was
made immunogenic by coupling the peptide to keyhole limpet hemocyanin (KLH; Pierce
Endogen, Rockford, IL, USA). The GnRH used in this study was synthesized at Macro-
molecular Resources, Colorado State University (Fort Collins, CO, USA) with the
structure [pEHWSYGLRPGGC-SH]. The underlined amino acids represent the native
GnRH molecule. A glycine was added at the C terminus as a spacer and a cysteine was
added to ensure consistent alignment of the peptide to the maleimide-activated protein
carrier KLH. The aqueous-based GnRH-KLH conjugate was combined in a 1:1 ratio by
volume with a novel adjuvant (AdjuVac1), which is an oil-based modified USDA-licensed
Johne’s disease vaccine (Mycopar1; Fort Dodge Animal Health, Fort Dodge, IA, USA)
containing small quantities of killed M. avium. The GnRH/KLH/AdjuVac1 vaccine has an
APHIS/USDA patent-pending status.
2.3. Treatment
Cats were divided into four treatment groups of three cats each. The sham group
received vaccines containing all components except GnRH-KLH. Three treatment
groups received vaccines containing 50, 200, or 400 mg GnRH-KLH. Brief anesthesia
was induced by administration of isoflurane (IsoFlo1; Abbott Laboratories, North
Chicago, IL, USA) by face mask. The hair from the right cranial thigh was clipped, and
the injection site was cleaned with 70% isopropyl alcohol. The vaccine (0.5 ml) was
injected into the quadriceps muscle group. The right pinna was tattooed with a code
indicating the treatment given.
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Potential adverse reactions to immunization were evaluated by daily physical examina-
tion, including inspection of the injection site and measurement of body temperature for 1
week following treatment. Body weights of the cats were recorded monthly.
2.4. Detection of GnRH antibodies
Blood (3 ml) was collected by jugular venipuncture monthly into serum separator
tubes. Serum was separated by centrifugation and stored at 20 8C until assayed for
GnRH antibodies by ELISA. Each 96-well plate was prepared by adding 100 ng of BSA-
GnRH antigen to each well and blocking with PBS-2% powdered milk. Since a KLH-
GnRH conjugate was used in the vaccine, BSA-GnRH was used to coat wells so that only
antibody to GnRH would be detected. Cat serum was tested at four-fold dilutions to end-
point titers. Two negative controls were run on each plate; one negative control was
buffer without cat serum and the other was pre-vaccination cat serum. High-titer cat
serum was used as the positive control. Antibody to GnRH was detected by rabbit anti-cat
IgG followed by goat anti-rabbit horse radish peroxidase (HRP) (Sigma Chemical Co.,
St. Louis, MO, USA). Color was developed by 3,30,5,50 tetramethylbenzidine (TMB)
(Sigma Chemical Co.).
2.5. Determination of serum testosterone concentration
Blood was collected monthly for determination of testosterone concentration. Serum
samples were analyzed for total testosterone by RIA (Coat-A-Count1; Diagnostic
Products Corporation, Los Angeles, CA, USA) according to the manufacturer’s instruc-
tions. The manufacturer reports a sensitivity of 4 ng/dl with within-run coefficient of
variation (CV) of 4–18% and between-run CV of 6–11%, depending on the testosterone
concentration.
2.6. Phenotypic responses
Scrotal volume was determined prior to treatment and at monthly intervals thereafter.
The height and width of each scrotal sac was measured with electronic calipers. The
volume of each sac was calculated according to the formula [length (cm)  width (cm) 
0.524] [13], and the total volume was determined by adding the volumes of the left and
right sacs together. Six months after treatment, the penis of each cat was examined for the
presence of testosterone-dependent spines [14]. Following castration, the paired testicular
weights of each cat were determined.
2.7. Semen analysis
Six months after treatment, cats were sedated by intramuscular injection of 35–45 mg
tiletamine-zolazepam (Telazol1; Fort Dodge Animal Health, Fort Dodge, IA, USA)
for electroejaculation. A Teflon rectal probe (1 cm in diameter  13 cm in length) with
three stainless steel electrodes (2.6 mm in width and 3.75 cm in length) and an AC
60-Hz sine wave electroejaculator with a variable transformer were used to deliver the
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electrical stimuli (P.T. Electronics, Boring, OR, USA). The standardized ejaculation
sequence was divided into three series of stimulations ranging from 2 to 5 Vas described
[13]. Ejaculates were immediately analyzed for volume, forward progressive motility,
and sperm count. Forward progressive motility percentages were estimated by sub-
jective microscopic examination at 200 magnification. Sperm concentration was
determined using a commercial diluent (Unopette1 microcollection system for
RBC; Becton Dickinson and Co., Franklin Lakes, NJ, USA) and standard hemacyt-
ometer. A 10-ul aliquot of the ejaculate was fixed in 1% glutaraldehyde for morpho-
logical examination. Smears prepared from fixed sperm were stained with eosin B/
nigrosin and evaluated with conventional light microscopy (200). A total of 200
spermatozoa were examined for each sample and were classified as normal, abnormal
head, abnormal midpiece, abnormal tail, and presence of proximal or distal cytoplasmic
droplets [13].
2.8. Pathologic evaluation of testes
Following castration, testicular tissue samples were collected, embedded in paraffin,
sectioned at 4 mm and stained with haematoxylin and eosin (H&E). Histological exam-
ination of the testicles was conducted by a veterinary pathologist blinded to the treatment
groups (J.W.R.). The examination included assessment of the populations of interstitial
(Leydig) cells, Sertoli cells, and the proliferation and maturation of spermatocytes/
spermatids. The average number of spermatids was obtained by counting the number
of mature spermatids located in the lumen of the seminiferous tubules from 10 random high
power fields (hpf).
2.9. Statistical analysis
Descriptive statistics (mean  S:E:) were calculated for each group. Normally distrib-
uted data compared over time (GnRH antibody titer, testosterone concentration, scrotal
size) were evaluated using one-way repeated measures analysis of variance. The Holm-
Sidak method pairwise multiple comparison procedure was used to identify the groups that
differed from the others. Nonparametric data (semen analysis, testes histology) were
evaluated using the Mann–Whitney rank sum test. The Spearman rank order correlation
test was used to evaluate the correlation of GnRH antibody titer with serum testosterone
concentration in data pooled from all time points. Differences were considered significant
when P < 0:05. All tests were performed using SigmaStat1 statistics software (SPSS Inc.,
Chicago, IL, USA).
3. Results
3.1. Reactions to treatment
Following treatment, body temperature remained normal. No inflammation or ten-
derness at the injection site was detected in any of the cats. Cats gained weight
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throughout the study, and there was no difference in weight gain among treatment
groups (P ¼ 0:7).
3.2. Detection of GnRH antibodies
GnRH antibodies were detected in all cats receiving GnRH vaccine, but not in sham-
treated cats, by 1 month post-treatment and persisted throughout the 6-month study. No
dose effect of GnRH was observed as titers were not significantly different between cats
treated with 50, 200, or 400 mg GnRH (P ¼ 0:5). A breakpoint in physiologic responses
was observed at titers of 32,000. Therefore, cats were divided into three groups: sham,
responders (antibody titer >32,000), and nonresponders (antibody titer 32,000). Six of
nine treated cats had a robust response to immunization characterized by GnRH antibody
titers >32,000. Three of nine treated cats had poor responses to GnRH treatment with
GnRH antibody titers of 4000–32,000 (Fig. 1).
3.3. Serum testosterone concentrations
Serum testosterone was undetectable in responder cats by 3 months post-treatment.
There was no significant change in testosterone concentrations in sham-treated cats
(P > 0:2) or nonresponder cats (P ¼ 0:05) compared to baseline values, except at 4
months, when testosterone increased transiently in sham-treated cats (P ¼ 0:01; Fig. 2).
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Fig. 1. GnRH antibody titer (mean S:E:) following a single treatment with a GnRH immunocontraceptive
vaccine (n ¼ 9) or sham treatment (n ¼ 3). Six treated cats were classified as responders (titer >32,000) and
three cats were nonresponders (titer 4000–32,000). Responders had significantly higher antibody titers than
nonresponders from 1 to 6 months post-GnRH treatment (P < 0:05).
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Serum testosterone concentration was negatively correlated with GnRH antibody titer
(r ¼ 0:77; P < 0:001).
3.4. Phenotypic responses
By 3 months post-treatment, testicular atrophy in cats responding to GnRH treat-
ment was evidenced by a sustained reduction in scrotal volume (P < 0:001). Scrotal
volume did not change over time in the sham-treated (P ¼ 0:05) and nonresponder cats
(P ¼ 0:5; Fig. 3) At 6 months post-treatment, testosterone-dependent penile spines
were well-developed in sham-treated cats and nonresponder cats, but were absent
from cats responding to GnRH treatment (Fig. 4). Combined testicular weights of
responder cats averaged 1:3 0:1 g and were lower than sham-treated controls
(5:3  1:3 g; P ¼ 0:02) and nonresponder cats (2:9 0:3 g; P ¼ 0:02). Testicular
weights of sham-treated cats were not different from those of nonresponder cats
(P ¼ 0:2).
3.5. Semen analysis
At 6 months, the three sham-treated cats had excellent semen quality characterized by high
sperm counts and progressive motility. Of the three nonresponder cats, two (2A, 4C) had
lower sperm counts with reduced motility, and one (3B) had normal semen quality (Table 1).
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Fig. 2. Serum testosterone concentration (mean S:E:) was significantly lower than pretreatment values in
responder cats by 3 months post-GnRH treatment (P < 0:05). Testosterone concentrations did not change
significantly in sham-treated (P ¼ 0:2) and nonresponder cats (P ¼ 0:05), except at 4 months when sham-treated
cats has a transient increase in testosterone (yP ¼ 0:01).
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Overall, the sperm concentration for sham-treated cats (70:3 26:8 106 sperm/ml) was
similar to that for nonresponder cats (39:4 19:4 106 sperm/ml; P ¼ 0:7). Likewise, total
sperm counts were similar for sham-treated cats (3:1 1:8 106 sperm) and nonresponders
cats (3:4 1:6 106 sperm; P ¼ 0:7). Only one (2C) of the six responder cats produced
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Fig. 3. Scrotal volume (mean S:E:) was significantly lower than pretreatment values in responder cats by 3
months post-GnRH treatment (P < 0:001). Scrotal volume did not change in sham-treated cats (P ¼ 0:05) and
nonresponder cats (P ¼ 0:5).
Table 1
GnRH antibody titer, testosterone concentration, semen characteristics, and physical findings of cats 6 months
after GnRH immunization
Cat Treatment
(mg GnRH)
GnRH
antibody
titer (103)
Serum
testosterone
(mg/dl)
Semen
volume
(ml)
Sperm
concentration
(number/ml
106)
Total
sperm
count
(106)
Sperm
motility
(%)
Combined
testes
weight (g)
Penile
spines
1A Sham 0 110 105 63 6.6 90 7.1 þ
1B Sham 0 240 50 28 1.4 85 3.0 þ
1C Sham 0 240 10 120 1.2 90 5.7 þ
2A 50 32 100 115 1.1 1.3 5 3.0 
2B 50 256 0 12 0 0 No sperm 1.2 
2C 50 128 0 15 0.01 0.0002 0 1.7 
3A 200 128 0 15 0 0 No sperm 1.3 
3B 200 32 10 35 64 2.2 80 2.3 þ
3C 200 128 0 10 0 0 No sperm 0.9 
4A 400 128 0 13 0 0 No sperm 1.5 
4B 400 128 0 12 0 0 No sperm 1.2 
4C 400 8 110 125 53 6.6 25 3.3 þ
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sperm, none of which were motile. The sperm concentration (0:01 106 sperm/ml) and total
sperm count (0:0002 106) for cat 2C were very low compared to the sham-treated and
nonresponders cats (Table 1). The percentage of sperm with normal morphology was similar
in sham-treated cats (58  12%) and the nonresponders cats (65 12%) (P ¼ 0:7). The
most common abnormalities in both groups were curved tail (13 4%), bent midpiece
(11 9%). and bent tail (13 8%).
Fig. 4. Marked testicular atrophy (A) was present 6 months after GnRH treatment of cat 4B (right) compared to
sham-treated cat 1C (left). Scale is in centimeters. Penile spines were well-developed in cat 1C (B) but were
absent in cat 4B (C).
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Fig. 5. Sham-treated control cats (A) exhibited large polyhedral interstitial cells expanding the interstitium (I).
The seminiferous tubules contained Sertoli cells (large arrows) supporting numerous germ cells (arrowheads)
with maturation evident to mature spermatids (small arrows). The most conspicuous cells present in the cats
responding to GnRH treatment (B) were vacuolated Sertoli cells (arrows, see also Fig. 6). Germ cells were not
easily identified in most regions and there were numerous scattered cells undergoing necrosis (arrowheads).
Interstitial cells (I) were pale and shrunken. H&E stain. Bar ¼ 115 mm.
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3.6. Pathologic evaluation of testes
Histologically, testicles from sham-treated cats exhibited a conspicuous population of
interstitial (Leydig) cells (Fig. 5A). In contrast, testicles from cats that responded to GnRH
treatment had marked interstitial cell atrophy (Fig. 5B). Morphologically, the interstitial
cells that were present were pale and shrunken compared to the plump, polyhedral
eosinophilic cells in sham-treated cats. Testicular seminiferous tubules from sham-treated
cats were uniformly populated by Sertoli cells and germ cells, and displayed normal
production and maturation of spermatids that were easily identified in tubular lumens
(Fig. 5A). In contrast, GnRH responder cats had marked tubular atrophy with vacuolated
Sertoli cells and a paucity of germ cells (Figs. 5B and 6). Even after examination of
numerous microscopic fields, mature spermatids could be identified in only three of the six
responder cats. The number of sperm/10 hpf in the responder cats (1:8 0:4) was lower
than the number in sham-treated cats (437  209; P ¼ 0:02) and nonresponder cats
(521  169; P ¼ 0:02).
4. Discussion
In this study, 12 sexually intact adult male cats were immunized once with 0–400 mg
GnRH. No injection site or systemic reactions were noted during the 6-month observation
period. As expected, the GnRH antibody titer was negatively correlated with serum
testosterone concentration. At final evaluation 6 months post-injection, six of nine treated
cats had GnRH antibody titers >64,000. These ‘‘responder’’ cats had undetectable serum
Fig. 6. Regionally, some of the responder cats had such extensive vacuolation of the Sertoli cells that the
seminiferous tubular lumen was obscured. H&E stain. Bar ¼ 250 mm.
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testosterone, marked testicular atrophy, and absence of viable sperm in semen samples.
Three of nine treated cats had a partial response to immunization with GnRH. These
‘‘nonresponders’’ had GnRH antibody titers of 4000–32,000 accompanied by intermediate
serum testosterone concentrations, testicular atrophy, and semen quality. Although tes-
tosterone and/or semen quality in nonresponders was decreased, variable numbers of
motile sperm were present in semen, indicating that fertility may not be completely
suppressed in cats with low GnRH antibody titers. Breeding trials were not performed to
confirm fertility in this pilot study.
The reason that some cats fail to produce high antibody titers against GnRH is unknown.
It does not appear to be dose-related, since cats in each dose group produced both high and
low titers. It is possible that in some cats the immune response was diverted to the carrier
protein (KLH), the mycobacterial adjuvant, or other vaccine components instead of GnRH.
The relative immune responses to the various components of the vaccine are currently
under investigation.
Immunocontraception was not achieved in a previous study [15] in which male cats were
treated three or four times with synthetic GnRH conjugated with tetanus toxoid and
adjuvanted with N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine. GnRH antibody titers
were similar to those detected in dogs that responded transiently to the same treatment,
but serum testosterone concentrations did not decrease in cats [15]. In another study, 4 male
and 10 female kittens were immunized with GnRH at 8 and 12 months and approximately 2
years of age. Serum testosterone concentrations were suppressed in three of four males for
the duration of the study. Reproductive activity was not observed in the females, but
hormone concentrations were not reported [16]. In another study in which LH receptors
(LHR) were targeted lower in the endocrine cascade, bovine LHR combined with N-
acetylglucosaminyl-(b1–4) N-acetylmuramyl-L-alanyl-D-isoglutamine adjuvant was admi-
nistered in silastic implants placed under the skin of female cats [17]. These implants were
followed by a series of four boosters administered intramuscularly to maintain LHR
antibody titers. The appearance of LHR antibodies was associated with decreased serum
progesterone concentrations and cessation of estrus cycling, but estrogen concentrations
were not affected. Recovery of estrus cycling occurred when antibody titers decreased
after1 year. Although the LHR study provided proof of principal that blockade of the
hypothalamic–pituitary–gonadal axis by immunocontraceptive vaccination may be effec-
tive in cats, the effect required multiple treatments and was relatively short-lived, making
such treatment impractical for use in free-roaming cats [17].
Most reports of GnRH immunocontraception outside of laboratory species have involved
juvenile food-producing species as an alternative to surgical gonadectomy of animals
intended for slaughter. In this situation, sterilization is performed to prevent undesirable
effects of sex hormones on estrus cycling, aggressive behavior, and androgen-related taint,
which reduce feed efficiency and carcass quality. In most reports, a series of prime-boost
treatments was given and the follow-up period was short. GnRH immunization resulted in
decreased testosterone, LH, and progesterone concentrations, testes size, estrus cycling,
libido, aggression, and androgen-related taint in calves [18–22], piglets [23–27], and lambs
[28–30]. Similar responses were observed in adult stallions [31] and cows [32].
GnRH immunocontraception has also been investigated for controlling ‘‘pest species’’
of wildlife, which present many of the same challenges encountered in control programs
J.K. Levy et al. / Theriogenology 62 (2004) 1116–1130 1127
for free-roaming feral cats. In adult female white tail deer given multiple treatments, estrus
cycling and progesterone were suppressed [9,10]. In some cases, does that did conceive
aborted their fetuses due to inadequate ovarian production of progesterone. Overall
fawning rates were markedly reduced compared to untreated control does. Male deer
treated with GnRH had decreased testosterone concentrations and testes size and poor
libido [9]. Antlers of male deer remained in velvet and were dropped earlier than in control
bucks. A single GnRH immunization was 100% effective in both female and male Norway
rats [11]. Immunity lasted >1 year in most rats, which may equate to the reproductive
lifespan of rats living in the wild. GnRH treatment resulted in high antibody titers in a
variety of other wildlife species requiring population control, including squirrels, rabbits,
coyotes, horses, bison, and pigs [12].
Promising results in multiple species suggest that GnRH immunocontraception may
represent a broad tool for population control of wildlife. However, in almost every report, a
series of treatments was required for adequate immunity and a portion of animals failed to
respond to treatment and remained fertile. Universally, physiologic responses were
correlated with GnRH antibody titer. Animals with high titers were sterile, whereas those
animals with lower titers were not. GnRH immunocontraception appears to be reversible
when antibody titers wane over time. While this may be desirable in the management of
some species, an ideal cat contraceptive would provide permanent sterilization. Wide-
spread use of immunocontraceptive vaccines for free-roaming cats in the field will require
the development of products that provide long-term immunity with a single treatment in a
high proportion of animals.
The results presented in this report suggest that GnRH may be an effective immunocon-
traceptive antigen for cats. GnRH is an ideal target, because, in addition to contraception,
the effect of its neutralization is to block the production of sex hormones such as estrogen
and testosterone, which contribute to objectionable behavior and medical diseases in cats. A
longer duration study in a larger number of cats of both sexes is necessary to determine
duration of immunity and true rate of efficacy of GnRH immunocontraception in cats.
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